Loading, Please Wait...

CST: 20/11/2019 02:34:14   

Altimmune to Announce Third Quarter 2019 Financial Results on November 14

13 Days ago

GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and nine months ended September 30, 2019 before the market opens and host a conference call on Thursday, November 14, 2019.

Conference Call Details
Date: Thursday, November 14
Time: 8:30 am Eastern Time
Domestic: 855-327-6837
International: 631-891-4304
Conference ID: 10008064
Webcast: http://public.viavid.com/index.php?id=136942

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAXTM and NasoShieldTM). For more information on Altimmune, please visit www.altimmune.com.

Contacts:
 
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com
Ashley R. Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?